Search Results

You are looking at 21 - 30 of 521 items for :

  • "Adjuvant therapy" x
  • Refine by Access: All x
Clear All
Full access

Point: Treating Stage II Colon Cancer: The Quest for Personalized Adjuvant Care

Maxwell T. Vergo and Al B. Benson III

risk reduction), which was nonsignificant. Both studies were underpowered to detect an OS benefit, and therefore definitive conclusions about 5-FU–based adjuvant therapy in stage II disease are difficult to draw from these studies. In contrast, 2

Full access

BPI24-200: Delays in Adjuvant Therapy in Head and Neck Cancers: Identifying Population Disparities and Implementing Solutions

Leena Abu-Zahra, Jazzmyne Adams, David Friedland, and Jennifer Bruening

rates of recurrence. 1 However, recent trends suggest a decreasing national compliance to this guideline, as most patients with HNSCC initiate PORT beyond this time frame. 2 Given the increasing delay to adjuvant therapy, this study seeks to identify

Full access

HSR22-180: Real-World Treatment Patterns and Outcomes of Targeted Therapy and Immunotherapy in BRAF+ Cutaneous Melanoma Patients Treated in the Adjuvant Setting

Sanjay Chandrasekaran, You-Li Ling, Jackson Tang, Deborah Norton, and Rohan Shah

: Recurrence-free survival with 1L DT or IO as adjuvant therapy for BRAF + melanoma

Full access

Abstracts From the NCCN 2024 Annual Conference

Testing, Surgical Outcomes, and Adjuvant Therapy Rates Among Patients With Resected Non–Small Cell Lung Cancer (NSCLC) in the Community Setting in the United States (US), 2019–2023 Xiaohan Hu, PhD, MPH 1 ; Yu-Han Kao, PhD 1 ; Ashwini Arunachalam, MPH

Full access

HSR24-161: Biomarker Testing, Surgical Outcomes, and Adjuvant Therapy Rates Among Patients With Resected Non–Small Cell Lung Cancer (NSCLC) in the Community Setting in the United States (US), 2019–2023

Xiaohan Hu, Yu-Han Kao, Ashwini Arunachalam, Diana Chirovsky, Yiru Wang, Chenan Zhang, Kaitlyn Kane, and Ayman Samkari

Background: The management of resectable early-stage NSCLC in the US has been rapidly evolving since late 2020 when the EGFR tyrosine kinase inhibitor (TKI) osimertinib was approved as adjuvant therapy for resected EGFR-mutated NSCLC. After

Full access

NCCN Guidelines and Quality Cancer Care: Where Have We Come From, and Where Should We Be Going?

Daniel G. Coit

guidelines for physicians treating patients with melanoma of all stages. We were to develop recommendations for the diagnosis, workup, initial treatment including adjuvant therapy, follow-up, and management of recurrent disease. Over the ensuing 2 decades

Full access

The Evolving Role of Neoadjuvant Therapy for Operable Breast Cancer

Laura M. Spring, Yael Bar, and Steven J. Isakoff

evolving neoadjuvant therapy trial designs. (A) Traditional neoadjuvant trials randomize all therapy preoperatively, followed by standard subtype-specific adjuvant therapy regardless of pathologic response. (B) Postneoadjuvant/residual disease trials

Full access

Management of Patients With Advanced Melanoma

Presented by: Genevieve Boland

adjuvant therapy trials of immune checkpoint inhibitors (ICIs) in stage III–IV melanoma and their outcomes. Figure 1. Adjuvant therapy in stage III–IV melanoma. Abbreviations: D/T, dabrafenib + trametinib; DMFS, distant metastasis–free survival; HR

Full access

Importance of Node Dissection in Relation to Neoadjuvant and Adjuvant Therapy

William C. Huang and Bernard H. Bochner

Since the advent of effective chemotherapeutic regimens for treating transitional cell carcinoma, multimodal therapy has become part of the contemporary management of patients with muscle-invasive bladder cancer. However, radical cystectomy with pelvic lymphadenectomy remains the cornerstone of treatment for patients with localized and regionally advanced muscle-invasive disease. The effectiveness of chemotherapy models in bladder cancer can depend greatly on the quality of surgery. Unfortunately, without sufficient level I data, the boundaries of lymphadenectomy and the diagnostic and therapeutic ramifications of variations in the pelvic lymph node dissection remain undetermined. This article examines the role of pelvic lymph node dissection during perioperative chemotherapy and discusses the current challenges in establishing standards for lymphadenectomy in patients undergoing treatment for muscle-invasive bladder cancer.

Full access

Melanoma, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology

Daniel G. Coit, John A. Thompson, Alain Algazi, Robert Andtbacka, Christopher K. Bichakjian, William E. Carson III, Gregory A. Daniels, Dominick DiMaio, Marc Ernstoff, Ryan C. Fields, Martin D. Fleming, Rene Gonzalez, Valerie Guild, Allan C. Halpern, F. Stephen Hodi Jr, Richard W. Joseph, Julie R. Lange, Mary C. Martini, Miguel A. Materin, Anthony J. Olszanski, Merrick I. Ross, April K. Salama, Joseph Skitzki, Jeff Sosman, Susan M. Swetter, Kenneth K. Tanabe, Javier F. Torres-Roca, Vijay Trisal, Marshall M. Urist, Nicole McMillian, and Anita Engh

statistically significant improvement in relapse-free survival ( Table 1 ). Intermediate-dose IFN, defined as 5 to 10 MU per day subcutaneously for 3 to 5 days per week, has also been compared with observation as adjuvant therapy for resected, high-risk melanoma